# OnCo record psk-krestin-adjuvant (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/psk-krestin-adjuvant/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "psk-krestin-adjuvant" ;
  schema:name "PSK (Krestin) mushroom polysaccharide as adjuvant therapy"@en ;
  schema:description "PSK, a protein-bound polysaccharide from the turkey tail mushroom, has been an approved adjuvant cancer drug in Japan since 1977. Meta-analyses of Japanese randomised trials in stomach and bowel cancer found a modest survival benefit added to chemotherapy, but these results have never been tested outside Japan."@en ;
  schema:url <https://onco.cc/technologies/psk-krestin-adjuvant/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Polysaccharide-K> ;
  schema:citation <https://doi.org/10.1007/s00262-006-0248-1>, <https://doi.org/10.1007/s00262-005-0054-1>, <https://www.cancer.gov/about-cancer/treatment/cam/hp/mushrooms-pdq> ;
  onco:status "approved" ;
  onco:tag "complementary", "supportive-care", "evidence:moderate" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/integrative-oncology/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sakamoto-cancer-immunol-immunother/>, <https://onco.cc/key-papers/paper-oba-cancer-immunol-immunother/> .